180M
Canines experiencing arthritis globally
1
Canine longevity treatments with conditional FDA approval
$18B
US companion animal pharmaceutical market
The majority of elderly canines will experience arthritis in their lives.
Degenerative disorders cascade: reduced mobility triggers muscle loss, adiposity gain, metabolic decline, and chronic inflammation. All of these, in turn, reduce lifespan....
Longevity
Can we meaningfully extend lifespan? Proving the effects of longevity treatments with our companions will help people believing that longevity treatments are attainable. Recently, the FDA began evaluating lifespan enhancing treatments for canines, and one company has even gained conditional approval to market their treatment.
Degenerative Disease
Reversing degeneration is essential to extending lifespan. Our studies will focus on whether it is possible to slow, or even reverse, the progression of degenerative diseases. We will eventually explore a combination of treatments to reach the best possible outcomes: people and their animal companions living without the burden of degenerative diseases.
Decentralized Trials
How can we conduct meaningful longevity science? What does a multi-treatment, multiple year study look like, and how can tokens incentivize long term participation? Dog Years may use tokens for trial participant referrals, for participating in a trial, or for providing follow up data after the main study has concluded.
＠dogyearsdao on 𝕏
Discord community
Dog Years DAO will convert clinical data into sustainable value through tiered licensing. The initial dataset on follistatin gene therapy outcomes will be licensed to biotech companies using a three-tier model, each with a corresponding fee and royal...
Science Translational Medicine
Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates
Science Advances
Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet–induced obesity
Companion Animal
